...
首页> 外文期刊>FEBS Open Bio >Gene expression profiles and pathway enrichment analysis of human osteosarcoma cells exposed to sorafenib
【24h】

Gene expression profiles and pathway enrichment analysis of human osteosarcoma cells exposed to sorafenib

机译:索拉非尼暴露的人骨肉瘤细胞的基因表达谱和途径富集分析

获取原文

摘要

Sorafenib is an inhibitor of a variety of tyrosine kinase receptors used to treat various cancers including hepatocellular, renal cell and thyroid carcinoma. It has been shown to change various targets associated with osteosarcoma, but the detailed mechanism remains unclear. In order to identify key genes, enriched pathways and important modules during the exposure of human osteosarcoma cells to sorafenib, data for gene expression profiles (GSE53155) were downloaded from the GEO database. In total, 61 differentially expressed genes (DEGs) were identified by the R bioconductor packages. Functional and enrichment analyses of DEGs were performed using the DAVID database. These revealed that DEGs were enriched in biological processes, molecular function and KEGG pathway of inflammatory immune response and angiogenesis. A protein–protein interaction network was constructed by string and visualized in cytoscape, and eight genes were selected as hubs: IL8,CXCL2,PTGS2,FOS,CXCL1, C3,EHMT2 and PGF. Subsequently, only one cluster was identified by mcode, which consisted of six nodes (CXCL1,CXCL2,PTGS2,FOS, C3 and PGF) and nine edges. PGF was the seed gene in this cluster. In conclusion, the results of this data mining and integration should help in revealing new mechanisms and targets of sorafenib in inhibiting osteosarcoma.
机译:索拉非尼是多种酪氨酸激酶受体的抑制剂,可用于治疗各种癌症,包括肝细胞癌,肾细胞癌和甲状腺癌。已经显示出它可以改变与骨肉瘤相关的各种靶标,但是其详细机制仍不清楚。为了鉴定人类骨肉瘤细胞暴露于索拉非尼期间的关键基因,丰富的途径和重要模块,从GEO数据库下载了基因表达谱数据(GSE53155)。 R生物导体包装共鉴定出61个差异表达基因(DEG)。使用DAVID数据库对DEG进行功能和富集分析。这些表明DEGs丰富了炎性免疫应答和血管生成的生物学过程,分子功能和KEGG途径。蛋白质-蛋白质相互作用网络是通过串构建的,并在细胞景观中可视化,并且选择了8个基因作为枢纽:IL8,CXCL2,PTGS2,FOS,CXCL1,C3,EHMT2和PGF。随后,通过mcode仅识别出一个群集,该群集由六个节点(CXCL1,CXCL2,PTGS2,FOS,C3和PGF)和九个边缘组成。 PGF是该簇中的种子基因。总之,这些数据挖掘和整合的结果应有助于揭示索拉非尼抑制骨肉瘤的新机制和靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号